Fineline Cube

Follow:
14483 Articles
AbbVie's SKYRIZI Hits AFFIRM Study Endpoints in Crohn's Disease – 55% Clinical Remission vs. 30% Placebo at Week 12
CompanyDrug

AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12

China's 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion
Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

CompanyDeals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

CompanyDrug

Ab&B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine – China’s First U.S.-Cleared Candidate Targets Immunocompromised Populations

Novo Nordisk's CagriSema Fails Non‑Inferiority Test Against Lilly's Zepbound in Phase III REDEFINE 4 Trial – 23% vs. 25.5% Weight Loss
CompanyDrug

Novo Nordisk’s CagriSema Fails Non‑Inferiority Test Against Lilly’s Zepbound in Phase III REDEFINE 4 Trial – 23% vs. 25.5% Weight Loss

Bayer Reports EUR 45.6 Billion 2025 Sales – Nubeqa and Kerendia Drive Pharma Growth Amid Xarelto Patent Cliff
Company

Bayer Reports EUR 45.6 Billion 2025 Sales – Nubeqa and Kerendia Drive Pharma Growth Amid Xarelto Patent Cliff

Company

Gilead Foundation Commits $12 Million to Community Health Worker HIV Prevention Initiative – 33 Organizations Across 15 U.S. Jurisdictions

Eli Lilly's Eloralintide Wins CDE Approval for Phase III Trials in China – Weekly Amylin Agonist Targets Weight Management Market
CompanyDrug

Eli Lilly’s Eloralintide Wins CDE Approval for Phase III Trials in China – Weekly Amylin Agonist Targets Weight Management Market

Pyrotech Therapeutics' PTT-936 Wins NMPA Approval – Novel ALPK1 Agonist Targets Bladder Cancer
CompanyDrug

Pyrotech Therapeutics’ PTT-936 Wins NMPA Approval – Novel ALPK1 Agonist Targets Bladder Cancer

CompanyDrug

Konruns Pharma’s KC1036 Wins NMPA Approval – Dual‑Target VEGFR2/AXL Inhibitor Enters IO Combination Trials

CompanyDeals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

CompanyDrug

Sichuan Biokin’s CD33 ADC BL-M11D1 Wins NMPA Approval – Expands into Myelodysplastic Syndromes